Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease... It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8.
- Mechanism
- Curator reviewed
Rivanicline is a (E)-metanicotine hemigalactarate. It effectively inhibits TNF- and LPS-induced IL-8 production in different cell types.
- Primary indication
- Investigated for use/treatment in ulcerative colitis.Curator reviewed
- Formula / weight
- C10H14N2 · 162.2316 g/mol (avg)
- Also known as
- (E)-metanicotine · trans-metanicotine
- Code names
- RJR-2403 · TC-2403
Resolves to
JUOSGGQXEBBCJB-GORDUTHDSA-NSMILESCNCC\C=C\C1=CN=CC=C1What you can answer from here — as of March 06, 2025
Which drugs share a target with Rivanicline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account